Technical Data
Emmprin (Extracellular Matrix Metalloproteinase (MMP) Inducer)
Degradation of the basement membrane by matrix metalloproteinases (MMPs) is an important step in the growth, invasion, metastasis, and angiogenesis of human tumors. MMP-2 and MMP-9 are key enzymes in the degradation of Type IV collagens, a major component of the basement membrane in cancer tissues. MMPs are secreted by stromal fibroblasts near tumor cell clusters, and may also be secreted by tumor cells themselves. EMMPRIN, or extracellular matrix metalloproteinase inducer, is a 58kD protein with two immunoglobulin domains that was originally purified from the plasma membrane of the human LX-1 lung carcinoma cell line. EMMPRIN has been localized on the outer surface of tumor cells, where it interacts with fibroblasts to stimulate the expression of MMPs. Although the mechanism of EMMPRIN’s regulatory action on MMPs is unknown, the p38 MAP kinase pathway has been implicated in the induction of MMP in dermal fibroblasts.

Suitable for use in ELISA, Western Blot and Immunohistochemistry. Other applications have not been tested.

Recommended Dilutions:
ELISA: 0.1-1.0ug/ml
Western Blot: 1-5ug/ml
Immunohistochemistry (FFPE): 10ug/ml Heat induced epitope retrieval (HIER) with EDTA, pH 8.0, is required prior to IHC staining.
Optimal dilutions to be determined by the researcher.

Positive Control:
Human breast cancer BT-20 and colon cancer SW480 cell lines.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
PabIgGAffinity Purified
100ug-20°CBlue IceHumanRabbit
Synthetic peptide corresponding to the N-terminal region of the human Emmprin protein.
Purified by immunoaffinity chromatography.
Supplied as a liquid in PBS, pH 7.4, 0.09% sodium azide.
Recognizes human Emmprin. On Western Blots, both the glycosylated (~55kD) and the non-glycosylated (30kD) forms of Emmprin are identified.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. MacDougall JR, et al. Cancer Met Rev 14(4):351-362, 1995.2. Sun J, Hemler ME. Cancer Res 61:2276-2281, 2001.3. Ellis SM, et al. Cancer Res 49(12):3385-3391, 1989.4. Lim M, et al. FEBS Lett 441:88-92, 1998.5. Seulberger H, et al. Neurosci Lett 140(1):93-97, 1992.6. Biswas C, et al. Cancer Res 55(2):434-439, 2000.7. Kasinrerk W, et al. J Immunol 149(3):847-854, 1992.8. Bordador LC, et al. Int J Cancer 85(3):347-352, 2000.9. Schuster VL, et al. Biochim Biophys Acta 1311(1):13-19, 1996.10. Polette M, et al. J Histochem Cytochem 45(5):703-709, 1997.